 |

Most deaths occur above
8,000 meters during descent from summit, high-altitude cerebral edema a common
problem
An international research
team led by Massachusetts General Hospital (MGH) investigators has conducted
the first detailed analysis of deaths during expeditions to the summit of Mt.
Everest. They found that most deaths occur during descents from the summit in
the so-called “death zone” above 8,000 meters and also identified factors that
appear to be associated with a greater risk of death, particularly symptoms of
high-altitude cerebral edema. The report, which will appear the December 20/27
issue of the British Medical Journal has been released online.
“We know that climbing
Everest is dangerous, but exactly how and why people have died had not been
studied,” says Paul Firth, MB, ChB, of the MGH Department of Anesthesia, who
led the study “It had been assumed that avalanches and falling ice –
particularly in the Khumbu Icefall on the Nepal route – were the leading
causes of death and that high-altitude pulmonary edema would be a common
problem at such extreme altitude. But our results do not support either
assumption.”
Thousands of climbers have
attempted to reach the summit of 8,850-meter (29,000-foot) Mount Everest since
the 1920s. In order to examine the circumstances surrounding all deaths on
Everest expeditions, the research team – which included investigators from
three British hospitals and the University of Toronto – reviewed available
expedition records including the Himalayan Database, a compilation of
information from all expeditions to 300 major peaks in the world’s highest
range. Of a total of reported 212 deaths on Everest from 1921 to 2006, 192
occurred above Base Camp, the last encampment before technical (roped)
climbing begins.
Firth and three physician
co-authors – all experienced Himalayan mountaineers with expertise in managing
high-altitude illness – reviewed records for all deaths and classified them
according to available information. More detailed analysis was conducted on
deaths occurring above 8,000 meters during the past 25 years. Deaths were
categorized as traumatic, from falls or external hazards such as avalanches;
nontraumatic, from high-altitude illness, hypothermia or other medical causes;
or as disappearances. Expedition participants were classified as either
‘climbers,’ individuals from outside the Himalayan region, or ‘sherpas’ –
high-altitude porters, most of them ethnic Sherpas or Tibetans, hired to
transport equipment and otherwise assist the climbers.
The overall mortality rate
for Everest mountaineers during the entire 86-year period was 1.3 percent; the
rate among climbers was 1.6 percent and the rate among sherpas was 1.1
percent. During the past 25 years, a period during which a greater percentage
of moutaineers climbed above 8,000 meters, the death rate for non-Himalayan
climbers descending via the longer Tibetan northeast ridge was 3.4 percent,
while on the shorter Nepal route it was 2.5 percent.
Factors most associated with
the risk of death were excessive fatigue, a tendency to fall behind other
climbers and arriving at the summit later in the day. Many of those who died
developed symptoms such as confusion, a loss of physical coordination and
unconsciousness, which suggest high-altitude cerebral edema, a swelling of the
brain that results from leakage of cerebral blood vessels. Symptoms of
high-altitude pulmonary edema, which is involved in most high-altitude-related
deaths, were suprisingly rare.
“High-altitude cerebral edema
symptoms were common among those that died, but signs of pulmonary edema, or
excessive fluid in the lungs, were unusual” Firth says. “We also were
surprised at how few people died due to avalanches and ice falls in recent
years – those usually happen at lower altitudes, and overwhelmingly people
died during summit bids above 8,000 feet – and that during descents, the
mortality rate for climbers was six time that of sherpas.”
While the reduced mortality
rate among sherpas during descent suggests that taking time to acclimatize to
high altitude could improve climber survival, Firth notes that many other
factors may be involved. “Most of the sherpas are born and live their lives
at high altitudes, and the competitive process for expedition employment
probably selects those who are best adapted to and most skilled for the work.
So the ability of lowlanders to acclimate to these very high altitudes needs
further investigation.”
During a 2004
Norwegian-American expedition from the north side of Everest led by Firth,
equipment problems led the team to turn around at 8,300 meters, return to
7,900 meters and pool their oxygen supply. Half of the team successfully
re-attempted the summit and returned safely, including Randi Skuag, the first
Norwegian woman to climb Everest. Seven other climbers from other teams that
year were not so fortunate – all dying above 8,000 meters, most while
descending from the summit.
“The majority of those who
have died on Everest were in the prime of their lives, with families and
friends left bereft,” stresses Firth, who is an instructor in Anaesthesia at
Harvard Medical School. “Mountaineering is for fun; it’s not worth dying or
leaving others there to die. Appropriate caution is the hallmark of the elite
mountaineer – the mountain will always be there next year.”
The senior author of the
British Medical Journal report is Richard Salisbury, who created and maintains
the Himalayan Database. The other physician reviewers are Jeremy Windsor, MD,
the Heart Hospital, London; Andrew Sutherland, MD, Radcliffe Hospital, Oxford;
and Christopher Imray, MD, University Hospital, Coventry, all in the U.K.
Additional co-authors are Hui Zheng, PhD, MGH Department of Medicine; G.W.
Kent Moore, PhD, and John Semple, MD, University of Toronto; and Robert Roach,
PhD, University of Colorado. The study was supported by the MGH Department of
Anesthesia and Critical Care.
Massachusetts General
Hospital , established in 1811, is the original and largest teaching hospital
of Harvard Medical School. The MGH conducts the largest hospital-based
research program in the United States, with an annual research budget of more
than $500 million and major research centers in AIDS, cardiovascular research,
cancer, computational and integrative biology, cutaneous biology, human
genetics, medical imaging, neurodegenerative disorders, regenerative medicine,
systems biology, transplantation biology and photomedicine.
 |
Millet One
Sport Everest Boot has made some minor changes by adding
more Kevlar. USES Expeditions / High
altitude / Mountaineering in extremely cold conditions / Isothermal to
-75°F Gore-Tex® Top dry / Evazote Reinforcements with aramid threads.
Avg. Weight: 5 lbs 13 oz Sizes: 5 - 14 DESCRIPTION Boot with semi-rigid
shell and built-in Gore-Tex® gaiter reinforced by aramid threads, and
removable inner slipper Automatic crampon attachment Non-compressive
fastening Double zip, so easier to put on Microcellular midsole to
increase insulation Removable inner slipper in aluminized alveolate
Fiberglass and carbon footbed Cordura + Evazote upper Elasticated
collar.
Expedition footwear for
mountaineering in conditions of extreme cold. NOTE US
SIZES LISTED. See more here. |
|
|
|

|
|  |